DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. by Scheen, André
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iemt20
Download by: [University of Liege] Date: 26 July 2016, At: 04:52
Expert Opinion on Drug Metabolism & Toxicology
ISSN: 1742-5255 (Print) 1744-7607 (Online) Journal homepage: http://www.tandfonline.com/loi/iemt20
DPP-4 inhibitor plus SGLT-2 inhibitor as
combination therapy for type 2 diabetes: from
rationale to clinical aspects
André J. Scheen
To cite this article: André J. Scheen (2016): DPP-4 inhibitor plus SGLT-2 inhibitor as
combination therapy for type 2 diabetes: from rationale to clinical aspects, Expert Opinion on
Drug Metabolism & Toxicology, DOI: 10.1080/17425255.2016.1215427
To link to this article:  http://dx.doi.org/10.1080/17425255.2016.1215427
Accepted author version posted online: 19
Jul 2016.
Published online: 19 Jul 2016.
Submit your article to this journal 
Article views: 33
View related articles 
View Crossmark data
Publisher: Taylor & Francis 




DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from 
rationale to clinical aspects  
 
 
André J. Scheen1,2 
 
1Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, 
Liège, Belgium 
2Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines 




Address for correspondence :    Pr André J. SCHEEN 
      Department of Medicine 
      CHU Sart Tilman (B35) 
      B-4000 LIEGE 1 
      BELGIUM 
      Phone : 32-4-3667238 
      FAX   : 32-4-3667068 


























Introduction :  Type 2 diabetes (T2D) is a complex disease with multiple defects, which 
generally require a combination of several pharmacological approaches to control 
hyperglycemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose 
cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach. 
Area covered: An extensive literature search was performed to analyze the pharmacokinetics, 
pharmacodynamics and clinical experience of different gliptin-gliflozin combinations.   
Expert opinion:  There is a strong rationale for combining a DPP-4i and a SGLT2i in patients 
with T2D because the two drugs exert different and complementary glucose-lowering effects. 
Dual therapy (initial combination or stepwise approach) is more potent than either 
monotherapy in patients treated with diet and exercise or already treated with metformin. 
Combining the two pharmacological options is safe and does not induce hypoglycemia. The 
additional glucose-lowering effect is more marked when a gliflozin is added to a gliptin than 
when a gliptin is added to a gliflozin. Two fixed-dose combinations (FDCs) are already 
available (saxagliptin-dapagliflozin and linagliptin-empagliflozin) and others are in current 
development. Bioequivalence of the two compounds given as FDC tablets was demonstrated 
when compared with coadministration of the individual tablets. FDCs could simplify the anti-
hyperglycaemic therapy and improve drug compliance. 
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Drug Summary box 
Drug name     Saxagliptin / dapagliflozin 
      Linagliptin / empagliflozin 
Phase      Available separately 
      Available as FDC (Qtern®, Glyxambi®) 
Indication     Treatment of patients with type 2 diabetes 
Pharmacology description   Saxagliptin, linagliptin  :  DPP-4 inhibitors  
      Dapagliflozin, empagliflozin : SGLT2 inhibitors 
        
Route administration    Oral 
Chemical structure 
       
 
Pivotal trial(s)     
 
Pharmacokinetic interactions:  [25,33] 
      
 
Clinical trials:     [27, 28, 29, 35, 36] 


























Article highlights box 
- Type 2 diabetes (T2D) often requires the combination of several medications with 
complementary actions to reach glucose control targets while limiting side effects 
- The combination of a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose 
cotransporter type 2 inhibitor (SGLT2i) is an attractive approach for the management of 
T2D.   
- Both saxagliptin plus dapagliflozin and linagliptin plus empagliflozin combined therapies 
have been tested as separate tablets (no clinically relevant pharmacokinetic drug-drug 
interactions) and as fixed-dose combination (FDC : bioequivalence studies). 
- DPP-4i – SGLT2i combined therapies are more efficacious than either monotherapy to 
control blood glucose, without worsening of the safety profile. 
- Initial DPP-4i – SGLT2i combination may be considered or one compound may the 




























Type 2 diabetes (T2D) is a complex disease with different pathophysiological defects 
[1]. If metformin, combined with lifestyle, is considered as the first pharmacological option, 
monotherapy fails to reach or maintain target glycated haemoglobin (HbA1c) when the 
disease progresses with time in a majority of T2D patients. Thus combination therapy is 
recommended soon or later in T2D. Various pharmacological approaches may be added to 
metformin as dual therapies or combined together as triple therapies, among which dipeptidyl 
peptidase inhibitors (DPP-4i) and/or sodium-glucose cotransporter type 2 inhibitors (SGLT2i)  
[2-5].   
 DPP-4i as oral incretin-based therapy are increasingly used in the management of T2D 
as an alternative or add-on therapy to other glucose-lowering agents, especially 
sulphonylureas [6]. They offer the advantage of an excellent safety profile with no increased 
risk of hypoglycaemia, weight gain and cardiovascular events (however, concern about a 
possible greater risk of hospitalization for congestive heart failure remains controversial) 
when compared to placebo [7]. SGLT2i, which target the kidney and promote glucosuria, 
belong to the newest pharmacological class of glucose-lowering agents [8]. Both their 
efficacy and safety have been recently reviewed [9, 10]. The demonstration of a remarkable 
reduction in cardiovascular and all-cause mortality with empagliflozin in T2D patients with 
history of cardiovascular disease in the EMPA-REG OUTCOME trial  [11] raised 
considerable interest among diabetologists and cardiologists, although the underlying 
mechanisms of protection remain largely unknown  [12]. 
DPP4i and SGLT2i exert their glucose-lowering effects via different and 
complementary mechanisms. When one single pharmacological class does not reach HbA1c 
target as monotherapy or even when added to metformin, a combination of a DPP-4i and a 
SGLT2i could be helpful in the management of patients with T2D [5, 13, 14]. Fixed-dose 
combinations (FDCs) have been recently commercialized, which could facilitate therapy and 
improve compliance of patients with T2D [15, 16]. 
The main aims of this review are the following ones: 1) to summarize the arguments 
supporting a combined used of a DPP-4i and a SGLT2i for the management of T2D; 2) to 
analyze the pharmacokinetic (PK) characteristics of gliptin-gliflozin administered separately 
or as FDCs; and 3) to describe the clinical efficacy and safety of DPP-4i-SGLT2i 
combinations, especially saxagliptin-dapagliflozin and linagliptin-empagliflozin, two FDCs 
recently available for the management of T2D. To identify relevant studies, an extensive 

























terms of DPP4i, alogliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, SGLT2i, 
canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, combined therapy and 
FDC. No language restrictions were imposed. Reference lists of original studies, narrative 
reviews and previous systematic reviews were also carefully examined. 
 
2. Rationale of DPP-4 inhibitor plus SGLT2 inhibitor combination  
 
Together, DPP-4i and SGLT2i fulfil a need for pharmacological agents with 
complementary mechanisms of action that can be used in combination to improve glucose 
control in a wide spectrum of patients with T2D, with a low risk of adverse events, such as 
hypoglycaemia or weight gain and the potential of cardiovascular protection (Table 1, Figure 
1)  [5, 13, 14]. 
DPP-4i enhance postprandial insulin secretion and suppress glucagon secretion by 
preventing the degradation of endogenously released incretin hormones [glucagon-like 
peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP)], two intestinal 
peptides whose concentrations physiologically increase after food intake [5]. Of major 
interest, DPP-4 inhibitors stimulate insulin secretion and inhibit glucagon secretion in a 
glucose-dependent manner, thus reducing hyperglycaemia while minimizing hypoglycaemia 
[6]. Furthermore, they do not induce weight gain and have proven their cardiovascular safety 
in several large prospective cardiovascular outcome studies [7]. 
SGLT2i, by specifically targeting the kidney, inhibit glucose reabsorption at the proximal 
tubule and thereby promote glucosuria, an effect independent of insulin. Because of the 
progressive deterioration of beta-cell function that characterizes T2D, a pharmacological 
mechanism of action that is independent of pancreatic beta-cell function makes SGLT2i an 
appropriate option for patients with advanced T2D, particularly if their glycaemic control is 
inadequate with other oral glucose-lowering agents. By promoting glucosuria and reducing 
hyperglycaemia, SGLT2i dampen glucotoxicity, which indirectly results in an improvement 
of beta-cell function and peripheral insulin sensitivity [17-19]. However, treatment with 
SGLT2i resulted in an increase in plasma glucagon concentrations, which was accompanied 
by a substantial increase in endogenous (hepatic) glucose production [17, 18]. The latter has 
been estimated to offset approximately half of the glucose excreted in the urine as a result of 
SGLT2i [17]. Thus, the addition of a DPP-4 inhibitor which inhibits glucagon and stimulates 
insulin secretion may have the potential to block the increase in endogenous glucose 

























these findings suggest that the combination of a DPP-4i with a SGLT2i would potentially 
provide additional help to individuals with T2D in reaching their glycaemic goal. Beyond a 
glucose-lowering effect, SGLT2i have some added value with reductions in body weight 
(including abdominal adiposity), blood pressure and serum uric acid, all markers considered 
as independent cardiovascular risk factors (Table 1) [8]. In EMPA-REG OUTCOME trial, 
empagliflozin, a selective SGLT2i, was associated with a remarkable reduction in 
cardiovascular and all-cause mortality in T2D patients with antecedents of cardiovascular 
disease [11, 12]. Because a marked reduction in the incidence rate of hospitalisation for heart 
failure was also reported with empagliflozin in EMPA-REG OUTCOME [20], contrasting 
with a higher rate of hospitalisation for heart failure with the DPP-4i saxagliptin in SAVOR-
TIMI 53 [21], one may speculate that combining a DPP4-i and a SGLT2i would be of 
potential interest regarding the risk of heart failure in patients with T2D [22]. 
Thus, combination treatment with a DPP-4i and/or SGLT2i appears to be an attractive 
option for patients with T2D starting pharmacological therapy, or for patients who are already 
treated with a glucose-lowering agent, especially metformin, but require additional 
medications to further improve glycaemic control. Available findings indicate that the 
underlying mechanisms of action of DPP-4i and SGLT2i not only complement a variety of 
other oral antidiabetics agents but also are complementary by themselves (Table 1, Figure 1)  
[5, 13, 14]. 
 
3. Saxagliptin plus dapagliflozin 
 
The potential therapeutic value of a combination therapy with saxagliptin and 
dapagliflozin for the treatment of T2D has been recently reviewed [23]. 
3.1 Pharmacokinetics 
The absolute oral bioavailability of saxagliptin and dapagliflozin was determined 
using simultaneous intravenous 14C-microdose/therapeutic oral dosing in healthy volunteers 
[24]. The geometric mean point estimates (90% confidence interval – CI –) values for 
saxagliptin and dapagliflozin were 50% (48, 53%) and 78% (73, 83%), respectively. The 
arithmetic mean half-life values for the intravenous and oral doses were similar (for 
saxagliptin: 7.5±0.6 and 5.7±0.4 h, respectively; for dapagliflozin: 12.2±5.3 and 13.7±3.4 h, 

























were parallel. Overall, the intravenous microdosing had similar pharmacokinetics to the 
therapeutic oral dosing [24]. 
The bioequivalence of saxagliptin/dapagliflozin 2.5/5 mg and 5/10 mg FDC tablets 
compared with coadministration of the individual tablets was evaluated in an open-label, 
randomised, single-dose crossover study in 72 healthy subjects [25]. Saxagliptin/dapagliflozin 
2.5/5 mg and 5/10 mg FDC tablets were bioequivalent to coadministration of the individual 
components in healthy subjects under fasted conditions (Table 2). Furthermore, this study 
investigated the potential influence of food and concluded that food had no clinically 
meaningful effect on the bioavailability of saxagliptin/dapagliflozin FDC [25]. 
3.2 Pharmacodynamics 
A study analyzed changes in plasma glucose, insulin, and glucagon in relation to 
glycaemic response after a liquid meal tolerance test during treatment with dual add-on of 
saxagliptin plus dapagliflozin  to metformin extended release compared with saxagliptin add-
on or dapagliflozin add-on alone in patients with T2D poorly controlled with metformin [26]. 
The combination of saxagliptin plus dapagliflozin provided additional reductions in glucose 
area under the curve from 0 to 180 minutes (AUC0-180 min) and HbA1c without the increase 
in plasma insulin seen with saxagliptin and without the increase in plasma glucagon seen with 
dapagliflozin. Changes in plasma insulin and glucose but not glucagon AUC0-180 min 
correlated with change in HbA1c [26]. 
3.3 Efficacy in clinical trials 
A double-blind trial randomised adults with poorly controlled T2D on background 
metformin to saxagliptin 5 mg/day plus dapagliflozin 10 mg/day, or saxagliptin 5 mg/day and 
placebo, or dapagliflozin 10 mg/day and placebo [27]. As a primary objective, changes from 
baseline in HbA1c were compared with the triple therapy versus each dual therapy at week 
24. Greater improvements in glycaemic control were obtained with the triple therapy by the 
dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of 
saxagliptin or dapagliflozin alone to background metformin monotherapy. The positive 
impact concerned the reduction in HbA1c, the proportion of patients reaching an HbA1c 
target < 7%, and the reductions in both fasting plasma glucose (FPG) and postprandial plasma 

























than with metformin plus saxagliptin but not than the reduction seen with metformin plus 
dapagliflozin. Even if the objective was not to compare metformin plus saxagliptin versus 
metformin plus dapagliflozin, it appears that the difference in blood glucose control was 
greater when the triple therapy was compared with the dual therapy metformin + saxagliptin 
than when compared with the dual therapy metformin plus dapagliflozin [27]. 
Two other randomised, double-blind, phase 3 trials in T2D patients evaluated the efficacy 
of a triple therapy combing metformin plus saxagliptin plus dapagliflozin but using a different 
protocol. One study tested the efficacy of adding  dapagliflozin 10 mg versus placebo to a 
saxagliptin plus metformin background therapy [28] whereas the other investigated the 
efficacy of adding saxagliptin 5 mg versus placebo to a dapagliflozin plus metformin 
background therapy [29] (Table 3). Treatment with dapagliflozin add-on to saxagliptin plus 
metformin resulted in a greater mean HbA1c reduction than placebo (-0.82 vs. -0.10%, P < 
0.0001) [28] whereas treatment with saxagliptin add-on to dapagliflozin plus metformin 
resulted in a less marked reduction in HbA1c (-0.51% versus -0.16% with placebo), but still 
highly significant (P < 0.0001) (Table 3) [29]. These differences translate into higher 
proportions of T2D patients reaching a target HbA1c < 7 % among those treated with the 
triple therapy compared to those receiving pacebo added to the background dual therapy [28, 
29]. 
3.4 Safety in clinical trials 
In a study comparing triple therapy by the dual addition of saxagliptin and dapagliflozin to 
dual therapies with the addition of saxagliptin or dapagliflozin alone in patients not well 
controlled by metformin, the proportion of patients with adverse events was similar across 
treatment groups [27]. Despite large decreases in HbA1c, hypoglycaemic event rates were 
low (around 1%) and similar across treatment groups, with no episodes of major 
hypoglycaemia [27]. Similar reassuring findings regarding the risk of hypoglyacemia were 
reported in two other studies having evaluated the safety of the triple therapy metformin-
saxagliptin-dapagliflozin [28, 29]. 
Urinary and genital infections occurred less frequently in patients receiving the triple 
therapy than in those receiving any of the dual therapies [27].  This unexpected finding was 
also observed in another study reporting a lower rate of genital infections when a saxagliptin 
was added to dapagliflozin compared with the SGLT2 inhibitor alone [29]. When 

























whom were women, had genital infections (5%) compared with those receiving placebo add-
on to saxagliptin plus metformin therapy (0.6%); however, the occurrence of urinary tract 
infections was similar for the dapagliflozin add-on to saxagliptin plus metformin group (5%) 
and placebo add-on to saxagliptin plus metformin group (6.3%) [28].  
No severe adverse effects such as pyelonephritis, acute pancreatitis or hospitalisation 
for heart failure were reported with the triple therapy metformin-saxagliptin-dapagliflozin in 
these three clinical trials of 24 weeks [27-29].   
 
4. Linagliptin plus empagliflozin 
The potential therapeutic value of a combination therapy with linagliptin and 
empagliflozin for the treatment of T2D has been recently reviewed [30, 31]. The single-pill 
combination (FDC) of linagliptin and empagliflozin, with their complementary mechanisms 
of action, is a promising treatment option for patients with T2D [15, 16, 32]. 
 
4.1 Pharmacokinetics 
In an open-label, randomised, multiple-dose, crossover study, sixteen healthy male 
subjects received empagliflozin 50 mg once daily for 5 days, both empagliflozin 50 mg once 
daily and linagliptin 5 mg once daily for 7 days, and linagliptin 5 mg once daily for 7 days 
[33]. Linagliptin total exposure and peak concentration was unaffected by coadministration of 
empagliflozin (Table 2). Similarly, empagliflozin total exposure was unaffected by 
coadministration of linagliptin. There was a reduction in empagliflozin peak exposure when 
linagliptin was coadministered, which was not considered clinically meaningful (Table 2). 
Thus, these data support the coadministration of empagliflozin and linagliptin without dose 
adjustments [33]. 
4.2 Pharmacodynamics 
Both empagliflozin and linagliptin improve glucose tolerance to a standardized test 
meal in patients with T2D, although via different mechanisms that may be complementary, as 
already discussed. After meal ingestion, empagliflozin 25 mg promoted glucosuria and was 
associated with significant reductions in plasma glucose and insulin AUC, which may be 
explained by improved beta-cell function and insulin sensitivity. In contrast, 

























production [18]. Following a meal tolerance test, linagliptin 5 mg significantly increased the 
two incretin hormones intact GLP-1 and GIP, but significantly lowered glucagon. These 
changes contributed to reduce postprandial hyperglycaemia in patients with T2D (Figure 1) 
[34]. 
4.3 Efficacy in clinical trials 
The efficacy of linagliptin/empagliflozin was evaluated in two studies of up to 52 weeks 
duration (primary endpoint assessed at week 24) in patients with T2D treated with diet and 
exercise [35] or with a metformin monotherapy [36]. In both studies, the single-pill 
combination of linagliptin and empagliflozin produced clinical improvements in glycaemic 
control that were generally superior to the improvements seen with each individual 
component, either linagliptin or empagliflozin alone. 
T2D patients not receiving antidiabetes therapy for at least 12 weeks were randomised to 
empagliflozin 25 mg/linagliptin 5 mg, empagliflozin 10 mg/linagliptin 5 mg, empagliflozin 25 
mg, empagliflozin 10 mg, or linagliptin 5 mg for 52 weeks [35]. Reductions in HbA1c at 
week 24 were significantly greater for empagliflozin 25 mg/linagliptin 5 mg compared with 
linagliptin 5 mg (P < 0.001) but not compared with empagliflozin 25 mg, and were 
significantly greater for empagliflozin 10 mg/linagliptin 5 mg compared with the linagliptin 5 
mg and empagliflozin 10 mg individual components (P < 0.001 for both). These changes 
translated in different proportions of patients with baseline HbA1c ≥ 7% who reached HbA1c 
< 7% at week 24 (Table 4). Similar differences were noticed for FPG levels (Table 4). 
Overall, efficacy was maintained at week 52. Thus, in this study, reductions from baseline in 
HbA1c with empagliflozin/linagliptin were significantly greater versus linagliptin 5 mg and 
empagliflozin 10 mg but not versus empagliflozin 25 mg [35]. 
To evaluate the efficacy of combinations of empagliflozin/linagliptin as second-line 
therapy, subjects with T2D inadequately controlled on metformin were randomised to a 
combination of empagliflozin 25 mg/linagliptin 5 mg, empagliflozin 10 mg/linagliptin 5 mg, 
empagliflozin 25 mg, empagliflozin 10 mg, or linagliptin 5 mg as add-on to metformin for 52 
weeks [36]. At week 24, reductions in HbA1c with empagliflozin/linagliptin were superior to 
those with empagliflozin or linagliptin alone when added to metformin (Table 4). With the 
triple therapy, more subjects with baseline HbA1c ≥ 7% had HbA1c <7% at week 24 

























FPG levels (Table 4). Again, glucose-lowering efficacy was maintained at week 52. Thus, 
combinations of empagliflozin/linagliptin as second-line therapy for 52 weeks significantly 
reduced HbA1c compared with the individual components [36]. 
4.3 Safety in clinical trials 
The overall safety profile of empagliflozin/linagliptin was similar to the known safety 
profiles of the individual components. In drug-naïve T2D patients, the proportion of subjects 
with adverse events over 52 weeks was similar across the three groups of patients treated with 
empagliflozin alone, linagliptin alone or a combination of the two glucose-lowering agents  
[35]. Adverse events leading to discontinuation, severe adverse events, and serious adverse 
events were noticed in slightly higher percentages of subjects with empagliflozin/linagliptin 
or empagliflozin alone compared with linagliptin alone [35]. However, overall the three 
treatments were well tolerated. Empagliflozin and linagliptin were associated with a low risk 
of hypoglycaemia when given as monotherapy, and no confirmed hypoglycaemic episodes 
were observed with empagliflozin/linagliptin combination [35]. In metformin-treated T2D 
patients, the proportion of subjects with one or more adverse events was similar across 
treatment groups receiving empagliflozin, linagliptin and the combination therapy [36]. 
Confirmed hypoglycaemic episodes (none requiring assistance) were reported in 3.6% of 
subjects on empagliflozin 25 mg/linagliptin 5 mg, 2.2% on empagliflozin 10 mg/linagliptin 5 
mg, 3.5% on empagliflozin 25 mg, 1.4% on empagliflozin 10 mg, and 2.3% on linagliptin 5 
mg. Interestingly, slightly lower rates of genital infections and urinary tract infections were 
reported when linagliptin was added to empagliflozin compared with the SGLT2 inhibitor 
alone [36]. In these two trials, no episodes of ketoacidosis were reported over a period of 52 
weeks, whatever the treatment arm considered, and only one case of pancreatitis has been 
noticed (among drug-naïve patients receiving empagliflozin 25mg/linagliptin 5mg)  [35, 36]. 
 
5. DPP-4i plus canagliflozin 
Besides dapagliflozin and empagliflozin, another SGLT2i canagliflozin  is 
commercialized both in the US and in Europe [37]. However, no specific studies evaluated 
the efficacy and safety of canagliflozin combined with a DPP-4i and no FDC is available yet. 
Of the 4330 patients in the large prospective cardiovascular outcome trial CANVAS, 
316 were taking DPP-4i (75.6 % sitagliptin and 22.5 % vildagliptin). At 18 weeks, 
canagliflozin provided significant placebo-subtracted reductions in HbA1c in patients taking 

























0.54) with canagliflozin 300 mg  [38]. Placebo-subtracted reductions in body weight (-2.0 kg 
with canagliflozin 100 mg and -2.7 kg with canagliflozin 300 mg) and systolic blood pressure 
(-4.7 mm Hg with both dosages) were noticed in patients already treated with DPP-4i. Higher 
incidences of genital mycotic infections and osmotic diuresis-related adverse events were seen 
with canagliflozin compared with placebo. Although the incidence of hypoglycaemia was 
numerically higher with canagliflozin versus placebo, nearly all events occurred in patients on 
background insulin or insulin secretagogues (sulphonylureas) [38]. In patients on background 
DPP-4i, canagliflozin improved HbA1c, body weight and systolic blood pressure, with an 
increased incidence of known adverse events related to SGLT2i. 
A 52-week open-label study performed in Japanese T2D evaluated the efficacy and 
safety of adding canagliflozin 100 mg or 200 mg once daily (doses used in Japan) to different 
background glucose-lowering therapies, including DPP-4i (sitagliptin, vildagliptin or 
alogliptin) [39]. The baseline to end-point change in HbA1c was -1.04% with canagliflozin 
100 mg (n=71) and -1.26% with canagliflozin 200 mg (n=74) in patients already treated with 
DPP-4i. These reductions were almost similar or slightly greater when compared with other 
subgroups receiving non-DPP-4i background glucose-lowering therapies. The addition of 
canagliflozin to a DPP-4i was also associated with significant reduction in FPG, body weight 
and systolic blood pressure. As expected from the properties of the combination drugs, the 
incidence of hypoglycaemia was much lower in patients treated with DPP-4i than in those 
treated with a sulphonylurea [39]. 
Oral teneligliptin is a DPP-4i indicated for the treatment of adults with T2D but it is 
commercialized only in some countries, i.e. in Japan (trade name: Tenelia®) [40] and 
Argentina (trade name: Teneglucon®)  [41]. Pharmacokinetic interactions of canagliflozin 
and teneligliptin were investigated in Japanese healthy adult men in an open-label, one-way 
crossover study using canagliflozin (200 mg/day) and teneligliptin (40 mg/day) [42]. A single 
dose of object drug (either canagliflozin or teneligliptin) was administered on day 1 followed 
by washout. After a continuous administration of precipitant drug (days 1 - 9), both drugs 
were concomitantly administered on day 7. No changes in exposure (AUC0 - 72h) and peak 
concentrations (Cmax) were observed for canagliflozin+teneligliptin versus monotherapy; 
geometric mean ratios for AUC0 - 72h and Cmax were 0.982 and 0.982 for the plasma 
concentration of canagliflozin and 0.983 and 0.976 for the plasma concentration of 
teneligliptin, respectively (Table 2). Thus, results showed no PK interaction between 


























6. SGLT2i combined with sitagliptin 
Other combinations have been investigated but only limited data are available yet and 
mainly restricted to pharmacokinetic studies looking for possible drug-drug interactions. 
Sitagliptin, the most widely used DPP4i worldwide [43], has been used as the reference 
DPP4i for such drug-drug interaction studies or clinical trials with various SGLT2i.  
 
6.1 Trials demonstrating the absence of drug-drug interactions  
Several studies investigated the potential pharmacokinetic drug-drug interactions between 
a SGLT2i and sitagliptin : no significant and clinically relevant interactions were reported as 
far as dapagliflozin  [44], ipragliflozin  [45], tofogliflozin  [46] and ertugliflozin  [47] were 
concerned. 
 
6.2 Dapagliflozin added to sitagliptin 
A randomised trial assessed the efficacy and safety of dapagliflozin 10 mg (n=225) 
versus placebo (n=226) as add-on therapy to sitagliptin 100 mg with or without metformin in 
patients with inadequately controlled T2D (mean baseline HbA1c 7.9%)  [48]. At 24 week 
add-on treatment with dapagliflozin provided additional clinical benefit with a significant 
reduction in HbA1c (-0.5% versus 0% with placebo) and body weight (-2.1kg versus -0.3 kg). 
Dapagliflozin also decreased HbA1c significantly versus placebo when added to sitagliptin 
alone (placebo-subtracted, –0.6%) or to sitagliptin plus metformin (placebo-subtracted, –
0.4%; both p<0.0001). Glycaemic and weight benefits observed at week 24 were maintained 
through week 48 and fewer patients receiving dapagliflozin were discontinued or rescued for 
failing to achieve glycaemic targets compared with placebo. Combined therapy was well 
tolerated except an increase in genital infections (9.8% with dapagliflozin versus 0.4% with 
placebo [48].  
 
6.3 Ertugliflozin added to sitagliptin 
Pfizer and Merck have a joint venture that is investigating an ertugliflozin/sitagliptin 
combination product. A clinical trial recently evaluated the efficacy and safety of a co-
administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or 
alone along with metformin in participants with T2D and inadequate glycaemic control on 
metformin monotherapy (ClinicalTrials.gov Identifier: NCT02099110). At 26 weeks, the co-
administration of ertugliflozin and sitagliptin was significantly more effective than 

























greater proportion of patients achieving an HbA1c treatment goal of less than 7.0%), and 
FPG; furthermore, ertugliflozin-sitagliptin combined therapy was significantly more effective 
in reducing body weight and systolic blood pressure compared to sitagliptin alone, which 
were secondary endpoints [49]. 
 
6.4 Innovative combination 
In patients with T2D, the combination of LX4211, a dual SGLT1/SGLT2 inhibitor, plus 
sitagliptin was associated with significantly increased active GLP-1, total GLP-1, and total 
peptide YY, with a significant reduction in total GIP, and with a significantly improved blood 
glucose level, with less insulin, compared with sitagliptin monotherapy. The dual 
SGLT1/SGLT2 inhibitor alone was associated with a significant increase in total GLP-1 and 
peptide YY and a reduced total GIP, likely due to a reduction in SGLT1-mediated intestinal 
glucose absorption, whereas sitagliptin alone was associated with suppression of all three 
peptides relative to baseline. All treatments were well tolerated, with no evidence of diarrhea 
(due to intestinal SGLT1 inhibition) with LX4211 treatment [50]. Although a dual 
SGLT1/SGLT2 inhibitor + DPP-4 inhibitor combination may provide an option in patients 
with T2D, the potential clinical benefits of such combination therapy need to be confirmed in 
further studies. 
7. Conclusion 
Treatment of T2D most often requires the combination of several glucose-lowering 
agents to tackle the various pathophysiological defects of the disease and maximize the 
chance of reaching individual HbA1c targets. The combination of a DPP-4i and a SGLT2i is 
attractive because their complementary modes of action contribute to improve blood glucose 
control in patients with T2D without deteriorating the safety/tolerance profile of each 
compound (on the contrary, a reduction in some adverse events may be expected). FDC 
formulations combining saxagliptin plus dapagliflozin and linagliptin plus empagliflozin are 
already commercialized and others combinations are currently investigated for the 
management of T2D. Although the precise positioning of a DPP-4i-SGLT2i combination 
should be better delineated by further studies, this approach appears to be a new option for the 
management of patients with T2D, with a good efficacy/safety ratio but at a higher cost. 

























The potential complementary mechanisms of action of DPP-4i and SGLT2i make 
these agents attractive treatment options for combination therapy. Theoretically, they could be 
used with any of the existing glucose-lowering agents in patients with T2D (except GLP-1 
receptor agonists), from metformin to insulin. Most available studies were performed in 
metformin-treated patients [27, 36] and there is a need for specific studies for instance in 
insulin-treated patients. Better glucose control was observed with combined DPP-4i and 
SGLT2i therapy in diet-treated [35] and metformin-treated [27, 36] patients when compared 
with individual component add-on therapy. Of potential interest may be the inhibitory effect 
on glucagon secretion exerted by the DPP-4i, which opposes to the stimulatory effect on 
glucagon secretion described with SGLT2i [17, 18]. Such SGLT2i-induced rise in glucagon 
secretion contributes to increase endogenous glucose production, which could somewhat limit 
the glucose-lowering effect resulting from enhanced glycosuria [17]. Furthermore, increased 
glucagon secretion was suspected to contribute to the development of ketoacidosis in T2D 
patients treated with SGLT2i, at least under special circumstances [51]. Thus, adding a DPP-
4i that reduces glucagon secretion in a glucose-dependent fashion may be a valuable option in 
T2D patients treated by SGLT2i. However, the opposite effects of DPP-4i and SGLT2i on 
glucagon secretion deserve further specific studies to better understand the potential benefit of 
this combination in this regard. Together, DPP-4i and SGLT2i fulfill a need for treatments 
with mechanisms of action that can be used in combination with a good safety profile and a 
low risk of adverse events, such as hypoglycaemia or weight gain. 
The safety profiles of DPP-4i [7] and SGLT2i [9] are well known. The safety profile 
of the DPP-4i-SGLT2i combination is comparable with that of each component prescribed 
separately. DPP-4i are generally well tolerated [7] while genital mycotic infections, 
predominantly in women, and, to a less extent, urinary tract infections are the most common 
reported adverse effects of SGLT2i  [9]. Interestingly, urinary and genital infections were less 
frequently observed with the addition of a DPP-4i to a SGLT2i in clinical trials with the 
combination saxagliptin-dapagliflozin  [27, 29] or linagliptin-empagliflozin  [36]. These 
observations may lead to speculation that DPP-4i could, by an unknown mechanism (either 
related to or independent of the additional glucose-lowering effect), protect against SGLT2i–
induced urinary and genital infections. None of these two pharmacological classes by itself is 
associated with a higher risk of hypoglycaemia although some hypoglycaemic episodes may 
be observed when each of them is added to a background therapy of sulphonylureas or 
insulin. A low risk of hypoglycaemic adverse events with a DPP-4i-SGLT2i combination, 

























DPP-4i saxagliptin has been suspected to increase the risk of heart failure [21] whereas 
SGLT2i exert an osmotic diuretic effect that could prevent the development of heart failure 
[20]. Although the risk of heart failure associated with DPP-4i remains uncertain [52], if 
present, it should be minimized by the addition of a SGLT2i, which has the capacity to 
promote both diuresis and natriuresis [12, 22]. 
The place of DPP-4i-SGLT2i combined therapy remains to be more precisely defined 
in the management of T2D [2, 3]. The glucose-lowering effect of the combined therapy was 
clearly greater with saxagliptin/dapagliflozin [27] or with linagliptin/empagliflozin [35, 36] 
than with each individual component. Furthermore, a single-pill combination of a DPP-4i and 
a SGLT2i, as recently commercialized for saxagliptin/dapagliflozin and 
linagliptin/empagliflozin, would reduce the daily pill burden in patients with T2D, potentially 
improving adherence to, and optimizing the benefits of therapy [15, 16]. However, the 
glucose-lowering effects of the two compounds were far from being additive and the final 
results, as far as the primary endpoint was concerned (HbA1c reduction at week 24), were 
somewhat disappointing. Overall, the added reduction in HbA1c when comparing DPP-4i-
SGLT2i combined therapy with SGLT2i alone was rather limited (only 0.2-0.4 %) in diet-
treated patients [35] or in metformin-treated patients [27, 36]. Consequently the add-on value 
of a DPP-4i appears less marked when it was added to a background therapy with metformin 
plus SGLT2i than when it was added to metformin alone. Indeed, in metformin-treated T2D 
patients, adding a DPP-4i has been shown to reduce HbA1c by about 0.6-0.8% [53] and be 
almost as effective as adding a sulphonylurea [54]. Despite the complementary mechanisms 
of DPP-4i and SGLT2i, it is thus difficult to systematically recommend the initiation of a 
combined therapy after failure of metformin monotherapy. The question that thus arises is 
which of the two pharmacological agents should be added first, either SGLT2i or DPP-4i, in 
T2D patients who do not reach individual HbA1c targets with metformin [55]. According to 
the results of a recent systematic review and network meta-analysis of clinical trials and 
compared to DPP-4i, almost similar  reductions in HbA1c were reported with dapagliflozin 
and empagliflozin but a greater reduction in HbA1c was observed with canagliflozin, 
especially at the dosage of  300 mg  [10]. Superiority of canagliflozin versus DPP-4i was 
confirmed in a recent real-world study [56]. When a SGLT2i was combined to metformin 
first, the additional glucose-lowering effect of prescribing a DPP-4i afterwards was rather 
limited [29]. In contrast, when a DPP-4i was combined to metformin first, the additional 

























These findings may help the physician in his/her therapeutic choice. However, 
secondary and tertiary add-on drug therapy should be individualized based not only on 
efficacy but also on tolerance and personal preferences, taking into account the wishes and 
priorities of the patient  [2, 3, 57]. DPP-4i have a better tolerance profile than SGLT2i and 
have proven to be well tolerated in elderly patients [7] while SGLT2i should be used with 
caution in this more fragile population [9]. Another advantage of DPP-4i is that these oral 
antidiabetic agents may be used in patients with renal impairment [58], whereas SGLT2i are 
contraindicated in patients with estimated glomerular filtration rate below 45 or 60 
ml/min/1.73m² (depending on the medication) [59]. Nevertheless, recent results from EMPA-
REG OUTCOME showed that empagliflozin was associated with slower 
progression of kidney disease and lower rates of clinically relevant renal events than was 
placebo when added to standard care in patients with T2D at high cardiovascular risk, and 
these findings may open new perspectives [60]. SGLT2i offer some advantages beyond the 
glucose-lowering effect, such as inducing weight loss, reducing systolic blood pressure, and 
improving cardiovascular outcomes in at risk patients, especially when heart failure is present. 
Therefore, SGLT2i may be preferred in T2D patients with obesity, hypertension, congestive 
heart failure and/or antecedents of cardiovascular events. Past history of cardiovascular 
disease or congestive heart failure may represent a key criterion of choice considering the 
remarkable efficacy of the SGLT2i empagliflozin in EMPA-REG OUTCOME  [11, 12], 
contrasting with previous mitigated  results reported with other glucose-lowering agents, 
including DPP-4i  [61]. Thus, in clinical practice, the choice should be individualized 
according to individual characteristics of the patient [62]. 
Finally, DPP-4i and SGLT2i are rather new oral antidiabetic agents that are more 
expensive than older compounds such as metformin and sulphonylureas.  In order for 
healthcare decision makers to ensure patients receive the highest standard of care within the 
available budget, the clinical benefits of each treatment option must be balanced against the 
economic consequences [63]. In patients with T2D treated with metformin, DPP-4i as add-on 
treatment may represent a cost-effective option compared with sulphonylureas [64]. 
Pharmaco-economic assessment of SGLT2i should take into account not only the magnitude 
of the glucose-lowering response [65], but also the potential benefits resulting from reduction 
in diabetes complications, including cardiovascular events [11, 12]. Further pharmaco-
economic analyses are needed to investigate the cost-effectiveness and cost-utility of a DPP-
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Figure 1: Illustration of the complementary glucose-lowering activities of DPP-4 inhibitors 
(DPP-4i) and SGLT2 inhibitors (SGLT2i) in type 2 diabetes. DPP-4 : dipeptidyl peptidase-4. 
SGLT2: Sodium-glucose cotransporter type 2. GIP: glucose-dependent insulinotropic 



























Table 1: Comparison of the metabolic, hormonal and clinical effects of DPP-4 inhibitors and 
SGLT2 inhibitors in patients with type 2 diabetes. 
 
Parameters DPP-4 inhibitor SGLT2 inhibitor 





Target organ Gut Kidney 
Mode of action Inhibition of degradation of 
GLP-1 and GIP (incretins) 
Inhibition of tubular 
reabsorption of glucose 
Glucosuria Unchanged/decreased (due to 
reduced hyperglycaemia) 
Increased (primary effect) 




Insulin secretion Increased (incretin effect, 
post-meal) 
Decreased (sparing effect) 




Peripheral insulin sensitivity Unchanged Increased 
Fasting plasma glucose Slightly decreased Decreased 
Postprandial plasma glucose Decreased Decreased 
HbA1c Decreased Decreased 
Body weight Unchanged Decreased 

























Lipid profile Almost unchanged Almost unchanged 
Serum uric acid Unchanged Decreased 
Cardiovascular outcomes Non-inferiority versus 
placebo (three trials) (**) 
Superiority versus placebo 
(in EMPA-REG 
OUTCOME) 
Hospitalisation for heart 
failure 
Increased (in SAVOR-TIMI 
53) 
Decreased (in EMPA-REG 
OUTCOME) 
Mortality (cardiovascular and 
all-cause) 
Unchanged (three non-
inferiority trials) (**) 
Decreased (in EMPA-REG 
OUTCOME) 
Renal events Not reported (three non-
inferiority trials) (**) 
Decreased (in EMPA-REG 
OUTCOME) 
 
(*) Medications available in United States and Europe 
(**) EXAMINE (alogliptin), SAVOR-TIMI 53 (saxagliptin), TECOS (sitagliptin) 



























Table 2: Results of pharmacokinetic interactions in studies combining saxagliptin plus dapagliflozin, linagliptin plus empagliflozin and 
teneligliptin plus canagliflozin. Data are adjusted geometric mean ratios (90% confidence interval). 
Single dose 
[25] 
n Dapagliflozin Saxagliptin 
Cmax AUC0-t Cmax AUC0-t 
Saxagliptin 2.5 mg 
/Dapagliflozin 5 mg FDC 
vs 
Saxagliptin 2.5 mg plus 









Saxagliptin 5 mg 
/Dapagliflozin 10 mg FDC 
vs 
Saxagliptin 5 mg plus 












n Empagliflozin Linagliptin 




























































mg/Empagliflozin 50 mg 
vs 
Linagliptin 5 mg 




Linagliptin 5 mg 
/Empagliflozin 50 mg 
vs 








n Canagliflozin Teneligliptin 
Cmax AUC 0-72h Cmax AUC 0-72h 
Teneligliptin 40 mg 
/Canagliflozin 200 mg  
vs 
Teneligliptin 40 mg 




Teneligliptin 40 mg 
/Canagliflozin 200 mg  
vs 

































































AUC : area under the plasma concentration-time curve 
Cmax : maximum observed plasma concentration 
FDC : fixed dose combination 
NA : not applicable 
 
 














































































































































































































a : versus Saxagliptin 
b: versus Dapagliflozin 
c : versus placebo 
NA : not available 
NS : not significant 



























































BW : body weight 
FPG : fasting plasma glucose 
HbA1c : glycated haemoglobin 





















































































































133 -2.1 -24.2 7.99 ± 0.97 -0.95 ± 0.06 41.5 
Empagliflozin 
10 mg 
132 -2.3 -22.4 8.05 ± 1.03 -0.83 ± 0.06 38.8 





























































et al  
2015 
[36] 


































140 -3.2 -18.8 8.02 ± 0.83 -0.62 ± 0.06 32.6 
Empagliflozin 
10 mg 
137 -2.5 -20.8 8.00 ± 0.93 -0.66 ± 0.06 28.0 
Linagliptin 5 
mg 
128 -0.7 -13.1 8.02 ± 0.90 -0.70 ± 0.06 36.1 
 
a: Versus Empagliflozin alone at corresponding dosage 



























































Delta : change from baseline 
BW : body weight 
FPG : fasting pasma glucose 
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